Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cysteine engineered fibronectin type III domain binding molecules

A cysteine, fibronectin technology, applied in the direction of peptide/protein components, immunoglobulins, animal/human proteins, etc.

Active Publication Date: 2016-08-24
JANSSEN BIOTECH INC
View PDF22 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, modification in cysteine ​​thiol groups obtained by mutation of various amino acid residues of the protein to cysteine ​​amino acids can be problematic, especially at unpaired (free Cys) residues or relative In the case of those residues susceptible to reaction or oxidation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cysteine engineered fibronectin type III domain binding molecules
  • Cysteine engineered fibronectin type III domain binding molecules
  • Cysteine engineered fibronectin type III domain binding molecules

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0364] Example 1: Construction of Tencon library

[0365] Tencon (SEQ ID NO: 1) is an immunoglobulin-like scaffold designed from the consensus sequence of fifteen FN3 domains from human tenascin-C fibronectin (FN3) domain type III (Jacobs et al., Protein Engineering, Design, and Selection, 25:107-117, 2012; US Patent Publication 2010 / 0216708). The crystal structure of Tencon shows six surface-exposed loops linking seven β-strands. Selected residues within the or each loop can be randomized in order to construct a type III fibronectin (FN3) domain library that can be used to select novel molecules that bind specific targets.

[0366] Tencon:

[0367] LPAPKNLVVSEVTEDSLRLSWTAPDAAFDSFLIQYQESEKVGEAINLTVPGSERSYDLTGLKPGTEYTVSIYGVKGGHRSNPLSAEFTT (SEQ ID NO 1):

[0368] Construction of TCL1 library

[0369] A library TCL1 designed to randomize only the FG loop of Tencon (SEQ ID NO: 1) was constructed for use with the cis-display system (Jacobs et al., Protein Engineering, Desig...

example 2

[0391] Example 2: Selection of Type III Fibronectin (FN3) Domains that Bind EGFR and Inhibit EGF Binding

[0392] library screening

[0393] Cis display was used to select EGFR binding domains from TCL1 and TCL2 libraries. The recombinant human extracellular domain of EGFR fused to IgGl Fc (R&D Systems) was biotinylated using standard methods and used for panning (residues 25-645 of full-length EGFR of SEQ ID NO: 73). For in vitro transcription and translation (ITT), 2-6 μg of library DNA was incubated with 0.1 mM intact amino acids, 1X S30 master mix components and 30 μL S30 extract (Promega) in a total volume of 100 μL and incubated at 30°C . After 1 hour, 450 μL of blocking solution (PBS pH 7.4 supplemented with 2% bovine serum albumin, 100 μg / mL herring sperm DNA and 1 mg / mL heparin) was added and the reaction was incubated on ice for 15 minutes. EGFR-Fc was assembled at 1:1 and 10:1 molar ratios of EGFR to EGF by mixing recombinant human EGF (R&D Systems) and bioti...

example 3

[0411] Example 3: Characterization of EGFR-binding FN3 domains that inhibit EGF binding

[0412] Large scale expression, purification and endotoxin removal

[0413] The nine FN3 domains shown in Table 4 were enlarged to provide more material for detailed characterization. Using overnight cultures containing each EGFR-binding FN3 domain variant, dilute the overnight culture 1 / 80 with 0.8 L of Terrific broth medium supplemented with 100 μg / mL ampicillin and inoculate into fresh medium, Incubate with shaking at 37°C. When the optical density at 600 nm reached about 1.2-1.5 by adding IPTG to a final concentration of 1 mM, the culture was induced and the temperature was lowered to 30°C. After 4 hours, cells were collected by centrifugation and the cell pellet was stored at -80°C until required for use.

[0414] For cell lysis, dissolve the thawed pellet at 5 mL per gram of pellet The ratio was resuspended in supplemented with 25U / mL (Sigma-Aldrich) and 1kU / mL rLysozyme ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
affinityaaaaaaaaaa
sizeaaaaaaaaaa
Login to View More

Abstract

The invention discloses cysteine engineered monospecific and bispecific EGFR and / or c-Met FN 3 domain containing molecules comprising one or more free cysteine amino acids. The molecules are prepared by mutagenizig a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules: and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

Description

technical field [0001] The present invention relates to binding molecules engineered with cysteine ​​residues, as well as methods of making them and using them. More specifically, the present invention relates to fibronectin type III (FN3) domain molecules that bind to cysteine ​​engineered EGFR and / or c-Met. Background technique [0002] Epidermal growth factor receptor (EGFR or ErbB1 or HER1) is a 170kDa transmembrane glycoprotein encoded by the c-erbB1 proto-oncogene. EGFR is a member of the human epidermal growth factor receptor (HER) family of receptor tyrosine kinases (RTKs), which includes HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4). These RTKs share a homologous structure consisting of a ligand-binding extracellular domain (ECD), a single transmembrane domain, and an intracellular domain containing a catalytic kinase domain and a C-terminal tail. EGFR signaling is initiated by ligand binding, which then induces conformational changes, dimerization, and trans-autop...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/22C12N1/20
CPCA61K2039/505A61P35/00A61P43/00C07K14/78C07K16/2863C07K2317/31C07K2317/73C07K2317/76C07K2317/92C07K2318/20C07K2319/00C07K2319/30C07K2319/31G01N33/74C12N15/70
Inventor S.戈德伯格S.贾科布斯T.林K.奥内尔
Owner JANSSEN BIOTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com